The week in pharma: action, reaction and insight – week to February 3, 2023
By Barbara Obstoj-Cardwell. Editor
Last Tuesday, Dutch gene therapy company uniQure announced a licensing deal with US start-up Apic Bio relating to the latter’s APB-102 to expand its pipeline of gene therapies for neurological disorders. In a heavy week for fourth-quarter and full-year financial results, Pfizer reported record-breaking figures, but warned that the covid factor is receding and that means lower sales and earnings from Comirnaty and Paxlovid. Fellow US fellow pharma major Eli Lilly, posted a down turn in revenues, with disappointing sales of obesity drug Mounjaro. Amgen launched its Amjevita in the USA, marking the first biosimilar to AbbVie’ mega-blockbuster Humira in the all-important American market and opening the floodgates to more copies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze